دورية أكاديمية
أعرض في EDS

Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy During the Fall Season Among Children with Persistent Asthma.

التفاصيل البيبلوغرافية
العنوان: Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy During the Fall Season Among Children with Persistent Asthma.
المؤلفون: Sheehan WJ; Children's National Hospital and George Washington University School of Medicine and Health Sciences, Washington, DC. Electronic address: wsheehan@childrensnational.org., Krouse RZ; Rho Federal Systems Division, Chapel Hill, NC., Calatroni A; Rho Federal Systems Division, Chapel Hill, NC., Gergen PJ; National Institute of Allergy and Infectious Diseases, Rockville, Md., Gern JE; University of Wisconsin School of Medicine and Public Health, Madison, Wis., Gill MA; University of Texas Southwestern Medical Center, Dallas, Tex., Gruchalla RS; University of Texas Southwestern Medical Center, Dallas, Tex., Khurana Hershey GK; Cincinnati Children's Hospital, Cincinnati, Ohio., Kattan M; College of Physicians and Surgeons, Columbia University, New York, NY., Kercsmar CM; Cincinnati Children's Hospital, Cincinnati, Ohio., Lamm CI; College of Physicians and Surgeons, Columbia University, New York, NY., Little FF; Boston University School of Medicine, Boston, Mass., Makhija MM; Lurie Children's Hospital and Northwestern University School of Medicine, Chicago, Ill., Searing DA; Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colo., Zoratti E; Henry Ford Health System and Wayne State University School of Medicine, Detroit, Mich., Busse WW; University of Wisconsin School of Medicine and Public Health, Madison, Wis., Teach SJ; Children's National Hospital and George Washington University School of Medicine and Health Sciences, Washington, DC.
مؤلفون مشاركون: NIAID-sponsored Inner-City Asthma Consortium
المصدر: The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2020 Oct; Vol. 8 (9), pp. 3021-3028.e2. Date of Electronic Publication: 2020 May 04.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101597220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2201 (Electronic) NLM ISO Abbreviation: J Allergy Clin Immunol Pract Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Elsevier Inc., [2013]-
مواضيع طبية MeSH: Anti-Asthmatic Agents*/therapeutic use , Asthma*/drug therapy , Asthma*/epidemiology , Eosinophilia*, Adolescent ; Adult ; Child ; Female ; Humans ; Immunoglobulin E ; Male ; Omalizumab/therapeutic use ; Seasons ; Young Adult
مستخلص: Background: Perennial aeroallergen sensitization is associated with greater asthma morbidity and is required for treatment with omalizumab.
Objective: To investigate the predictive relationship between the number of aeroallergen sensitizations, total serum IgE, and serum eosinophil count, and response to omalizumab in children and adolescents with asthma treated during the fall season.
Methods: This analysis includes inner-city patients with persistent asthma and recent exacerbations aged 6-20 years comprising the placebo- and omalizumab-treated groups in 2 completed randomized clinical trials, the Inner-City Anti-IgE Therapy for Asthma study and the Preventative Omalizumab or Step-Up Therapy for Fall Exacerbations study. Logistic regression modeled the relationship between greater degrees of markers of allergic inflammation and the primary outcome of fall season asthma exacerbations.
Results: The analysis included 761 participants who were 62% male and 59% African American with a median age of 10 years. Fall asthma exacerbations were significantly higher in children with greater numbers of aeroallergen-specific sensitizations in the placebo group (odds ratio [OR], 1.33; 95% confidence interval [CI], 1.11-1.60; P < .01), but not in the omalizumab-treated children (OR, 1.08; 95% CI, 0.91-1.28; P = .37), indicating a significant differential effect (P < .01). Likewise, there was a differential effect of omalizumab treatment in children with greater baseline total serum IgE levels (P < .01) or greater baseline serum eosinophil counts (P < .01). Multiple aeroallergen sensitization was the best predictor of response to omalizumab; treated participants sensitized to ≥4 different groups of aeroallergens had a 51% reduction in the odds of a fall exacerbation (OR, 0.49; 95% CI, 0.30-0.81; P < .01).
Conclusions: In preventing fall season asthma exacerbations, treatment with omalizumab was most beneficial in children with a greater degree of allergic inflammation.
(Copyright © 2020 American Academy of Allergy, Asthma & Immunology. All rights reserved.)
References: Int J Biostat. 2016 May 1;12(1):45-63. (PMID: 27227717)
Pediatr Allergy Immunol Pulmonol. 2018 Sep 1;31(3):119-131. (PMID: 30283711)
Curr Opin Allergy Clin Immunol. 2019 Apr;19(2):141-147. (PMID: 30649013)
Immunol Allergy Clin North Am. 2015 Feb;35(1):101-14. (PMID: 25459579)
J Allergy Clin Immunol. 2015 Dec;136(6):1476-1485. (PMID: 26518090)
J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138. (PMID: 17983880)
Chest. 2004 Apr;125(4):1378-86. (PMID: 15078749)
J Allergy Clin Immunol. 2013 Aug;132(2):485-6.e11. (PMID: 23591271)
Respir Med. 2007 Jul;101(7):1483-92. (PMID: 17339107)
J Allergy Clin Immunol Pract. 2013 Mar;1(2):163-71. (PMID: 24565455)
J Allergy Clin Immunol. 2015 Jun;135(6):1465-73.e5. (PMID: 25794658)
J Allergy Clin Immunol. 2012 May;129(5):1229-35. (PMID: 22326484)
Eur Respir J. 2007 Sep;30(3):452-6. (PMID: 17537763)
Cochrane Database Syst Rev. 2014 Jan 13;(1):CD003559. (PMID: 24414989)
N Engl J Med. 2006 Jun 22;354(25):2689-95. (PMID: 16790701)
Allergy. 2010 Sep;65(9):1141-8. (PMID: 20148804)
Am J Respir Crit Care Med. 2013 Apr 15;187(8):804-11. (PMID: 23471469)
Allergy. 2005 Mar;60(3):309-16. (PMID: 15679715)
Allergy. 2018 Feb;73(2):490-497. (PMID: 28859263)
N Engl J Med. 2011 Mar 17;364(11):1005-15. (PMID: 21410369)
Am J Respir Crit Care Med. 2009 Jul 1;180(1):59-99. (PMID: 19535666)
معلومات مُعتمدة: UL1 TR000154 United States TR NCATS NIH HHS; UL1 TR000150 United States TR NCATS NIH HHS; L40 AI107923 United States AI NIAID NIH HHS; UL1 TR000075 United States TR NCATS NIH HHS; R01 AI098077 United States AI NIAID NIH HHS; UL1 TR000040 United States TR NCATS NIH HHS; UL1 TR001105 United States TR NCATS NIH HHS; K23 AI104780 United States AI NIAID NIH HHS; HHSN272201000052I United States AI NIAID NIH HHS; HHSN272200900052C United States AI NIAID NIH HHS; UM2 AI117870 United States AI NIAID NIH HHS; UM1 AI109565 United States AI NIAID NIH HHS; UL1 RR025780 United States RR NCRR NIH HHS; UL1 TR001082 United States TR NCATS NIH HHS; UL1 TR000077 United States TR NCATS NIH HHS; UL1 TR000451 United States TR NCATS NIH HHS
فهرسة مساهمة: Keywords: Aeroallergen sensitization; Allergic inflammation; Asthma; IgE; Omalizumab
المشرفين على المادة: 0 (Anti-Asthmatic Agents)
2P471X1Z11 (Omalizumab)
37341-29-0 (Immunoglobulin E)
تواريخ الأحداث: Date Created: 20200508 Date Completed: 20210514 Latest Revision: 20230811
رمز التحديث: 20230811
مُعرف محوري في PubMed: PMC8775809
DOI: 10.1016/j.jaip.2020.03.051
PMID: 32376491
قاعدة البيانات: MEDLINE
الوصف
تدمد:2213-2201
DOI:10.1016/j.jaip.2020.03.051